N-methyl-N'-n-butylthiourea | 13278-51-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫脲类
• 英文名称: N-methyl-N'-n-butylthiourea
• 英文别名: N-methyl-N'-butylthiourea；N-butyl-N'-methyl-thiourea；N-Butyl-N'-methyl-thioharnstoff；N-Methyl-N'-n-butyl-thioharnstoff；N-Methyl-N'-butyl-thioharnstoff；1-Methyl-3-butyl-thioharnstoff；1-Butyl-3-methylthiourea
• CAS: 13278-51-8
• 化学式: C₆H₁₄N₂S
• mdl: MFCD06088332
• 分子量: 146.257
• InChiKey: PBOQJGMFSBTLHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-methyl-N'-n-butylthiourea 在 盐酸 、 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.5h， 生成 2H-Pyrido(3,2-e)(1,3)thiazine-5-carboxylic acid, 3,4-dihydro-2-(butylimino)-3,7-dimethyl-4-oxo-, methyl ester
  参考文献：
  名称：

  Zawisza; Siwinska; Sladowska, Farmaco, Edizione Scientifica, 1982, vol. 37, # 4, p. 266 - 274

  摘要：

  DOI：
• 作为产物：
  描述：

  丁基异硫氰酸酯 、 甲胺 以 乙醇 为溶剂， 生成 N-methyl-N'-n-butylthiourea
  参考文献：
  名称：

  Collard-Charon,C.; Renson,M., Bulletin des Societes Chimiques Belges, 1963, vol. 72, p. 149 - 165

  摘要：

  DOI：

文献信息

• 5-Lipoxygenase-Activating Protein Inhibitor
  申请人：SCHAAB Kevin Murray

  公开号：US20090291981A1

  公开（公告）日：2009-11-26

  Described herein is the FLAP inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, including solvates, and polymorphs thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the FLAP inhibitor, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.

  描述了一种FLAP抑制剂：3-[3-叔丁基硫基-1-[4-(6-乙氧基-吡啶-3-基)-苄基]-5-(5-甲基-吡啶-2-基甲氧基)-1H-吲哚-2-基]-2,2-二甲基丙酸，或其药用可接受盐。还描述了制备该FLAP抑制剂的方法，或其药用可接受盐，包括水合物和其多晶型。还描述了适合给予哺乳动物的药物组合物，包括FLAP抑制剂，或其药用可接受盐，以及使用此类药物组合物治疗呼吸系统疾病或疾病的方法，以及治疗其他白三烯依赖性或白三烯介导的条件或疾病的方法。
• PROCESS FOR THE PREPARATION OF ABIRATERONE AND INTERMEDIATES THEREOF
  申请人：ScinoPharm Taiwan, LTD.

  公开号：US20150005489A1

  公开（公告）日：2015-01-01

  The present invention provides intermediates for preparing abiraterone, and processes for preparing abiraterone and intermediates thereof. The intermediates include a compound of formula (IV): wherein R represents a hydroxy-protecting group.

  本发明提供了用于制备阿比特隆的中间体，以及用于制备阿比特隆及其中间体的方法。中间体包括式（IV）的化合物： 其中R代表一个羟基保护基团。
• Method and composition for rejuvinating cells, tissues organs, hair and nails
  申请人：——

  公开号：US20020188015A1

  公开（公告）日：2002-12-12

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一个实施例中，本发明涉及包含药物组合物的化合物和组合物，其中药物组合物包含这些化合物，并且相关方法解耦蛋白质、脂质、核酸和其他生物材料以及它们的任意组合的糖介导偶联。在另一个实施例中，这些组合物和相关方法在体内具有实用性，用于减少生物体暴露于内部摄入、经皮应用或其他方式的化合物或组合物时，糖介导偶联过程的有害影响。在另一个实施例中，这些组合物和相关方法对器官、细胞和组织的离体处理以及头发、指甲和皮肤的外部处理具有用处，通过改变可变性和增加组织扩散系数来使它们恢复活力。在另一个实施例中，本发明涉及新颖的化合物和药物组合物。
• Synthesis of Thiohydantoins by Phosphine-Catalyzed Reaction of Thioureas with Arylpropiolates
  作者：Olivier Loreau、Frédéric Taran、Michael Carboni、Jean-Marie Gomis

  DOI：10.1055/s-2008-1032024

  日期：2008.2

  A simple and efficient method for constructing thiohydantoin heterocycles using a phosphine-catalyzed tandem umpo­lung addition and intramolecular cyclization of thioureas on arylpropiolates is described.

  描述了一种简单有效的方法，利用膦催化的串联反转加成和亚硫脲在芳基丙炔酸酯上的环内缩合构建硫酰脲杂环。
• DP2 Antagonist and Uses Thereof
  申请人：BRITTAIN Jason Edward

  公开号：US20110034558A1

  公开（公告）日：2011-02-10

  Described herein is the DP 2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP 2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D 2 -dependent or prostaglandin D 2 -mediated diseases or conditions.

  本文描述了DP2拮抗剂[2'-(3-苄基-1-乙基-脲甲基)-6-甲氧基-4'-三氟甲基-联苯-3-基]-乙酸，或其药用盐。还描述了制备DP2拮抗剂或其药用盐的方法。本文还描述了适合用于哺乳动物的药物组合物，包括DP2拮抗剂或其药用盐，并描述了使用这种药物组合物治疗呼吸道疾病或症状、过敏性疾病或症状、炎症性疾病或症状，以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或症状的方法。